Claims
- 1. A method of reducing inflammation in a mammal comprising:
administering an antibody, antibody fragment or single chain antibody which binds to a receptor of IL-20, wherein said receptor is comprised of an IL-20RA subunit and an IL-20RB subunit; in an amount of a composition of the antibody, antibody fragment or single chain antibody sufficient to reduce inflammation.
- 2. The method of claim 1 wherein the inflammation comprises an inflammatory skin disease or arthritis.
- 3. The method of claim 2, wherein the inflammatory skin disease is selected from the group consisting of psoriasis, eczema, atopic dermatitis and contact dermatitis.
- 4. The method of claim 1, wherein the inflammation comprises an inflammatory lung disease.
- 5. The method of claim 4, wherein the inflammatory lung disease is selected from the group consisting of adult respiratory disease, asthma, bronchitis and pneumonia.
- 6. The method of claim 1, wherein the antibody, antibody fragment or single chain antibody is administered in combination with a lubricant, keratolytic, topical corticosteroid, topical vitamin D derivative, anthralin, systemic antimetabolite, methotrexate, psoralen-ultraviolet-light therapy (PUVA), etretinate, isotretinoin, cyclosporine, or calcipotriol.
- 7. A method of reducing inflammation in a mammal comprising:
administering an antibody, antibody fragment or single chain antibody which binds to a receptor of IL-20, wherein said receptor is comprised of an IL-20RA subunit and an IL-20RB subunit, and wherein the antibody, antibody fragment or single chain antibody specifically binds to the IL-20RA subunit of the receptor of IL-20; in an amount of a composition of the antibody, antibody fragment or single chain antibody sufficient to reduce inflammation.
- 8. The method of claim 7 wherein the inflammation comprises an inflammatory skin disease or arthritis.
- 9. The method of claim 8, wherein the inflammatory skin disease is selected from the group consisting of psoriasis, eczema, atopic dermatitis and contact dermatitis.
- 10. The method of claim 7 wherein the inflammation comprises an inflammatory lung disease.
- 11. The method of claim 10, wherein the inflammatory lung disease is selected from the group consisting of adult respiratory disease, asthma, bronchitis and pneumonia.
- 12. The method of claim 7, wherein the antibody, antibody fragment or single chain antibody is administered in combination with a lubricant, keratolytic, topical corticosteroid, topical vitamin D derivative, anthralin, systemic antimetabolite, methotrexate, psoralen-ultraviolet-light therapy (PUVA), etretinate, isotretinoin, cyclosporine, or calcipotriol.
- 13. A method of suppressing or reducing an inflammatory response in a mammal with inflammation comprising:
(1) determining a level of a proinflammatory cytokine protein; (2) administering a composition in an acceptable pharmaceutical vehicle comprising an antibody, antibody fragment or single chain antibody which binds to the receptor of IL-20, wherein said receptor is comprised of an IL-20RA subunit and an IL-20RB subunit; (3) determining a post administration level of proinflammatory cytokine protein; (4) comparing the level of serum proinflammatory cytokine protein in step (1) to the level of serum proinflammatory cytokine protein in step (3), wherein a lack of increase or a decrease in serum proinflammatory cytokine protein level is indicative of suppressing or reducing an inflammatory response.
- 14. A method of suppressing or reducing an inflammatory response according to claim 13, wherein the antibody, antibody fragment or single chain antibody specifically binds to the IL-20RA subunit of the receptor of IL-20.
- 15. A method of suppressing or reducing an inflammatory response according to claim 13, wherein the proinflammatory cytokine protein is IL-20, IL-8, or GM-CSF.
- 16. The method of claim 13 wherein the inflammation comprises an inflammatory skin disease or arthritis.
- 17. The method of claim 16, wherein the inflammatory skin disease is selected from the group consisting of psoriasis, eczema, atopic dermatitis and contact dermatitis.
- 18. The method of claim 13 wherein the inflammation comprises an inflammatory lung disease.
- 19. The method of claim 18, wherein the inflammatory lung disease is selected from the group consisting of adult respiratory disease, asthma, bronchitis and pneumonia.
- 20. The method of claim 13, wherein the antibody, antibody fragment or single chain antibody is administered in combination with a lubricant, keratolytic, topical corticosteroid, topical vitamin D derivative, anthralin, systemic antimetabolite, methotrexate, psoralen-ultraviolet-light therapy (PUVA), etretinate, isotretinoin, cyclosporine, or calcipotriol.
- 21. A method of treating a mammal afflicted with an inflammatory disease in which IL-20 plays a role, comprising:
administering an antagonist of IL-20 to the mammal such that the inflammation is reduced, wherein the antagonist is selected from the group consisting of an antibody, antibody fragment or single chain antibody; and wherein the antibody, antibody fragment or single chain antibody specifically binds to a IL-20RA subunit of a receptor of IL-20.
- 22. The method of claim 21 wherein the inflammation comprises an inflammatory skin disease or arthritis.
- 23. The method of claim 22, wherein the inflammatory skin disease is selected from the group consisting of psoriasis, eczema, atopic dermatitis and contact dermatitis.
- 24. The method of claim 21 wherein the inflammation comprises an inflammatory lung disease.
- 25. The method of claim 24, wherein the inflammatory lung disease is selected from the group consisting of adult respiratory disease, asthma, bronchitis and pneumonia.
- 26. The method of claim 21, wherein the antibody, antibody fragment or single chain antibody is administered in combination with a lubricant, keratolytic, topical corticosteroid, topical vitamin D derivative, anthralin, systemic antimetabolite, methotrexate, psoralen-ultraviolet-light therapy (PUVA), etretinate, isotretinoin, cyclosporine, or calcipotriol.
- 27. A method of suppressing or reducing proliferation or differentiation of keratinocyte cells in a mammal with inflammation comprising:
(1) determining a level of keratinocyte cells in a tissue sample; (2) administering a composition in an acceptable pharmaceutical vehicle comprising an antibody, antibody fragment or single chain antibody which binds to the receptor of IL-20, wherein said receptor is comprised of an IL-20RA subunit and an IL-20RB subunit; (3) determining a post administration level of keratinocyte cells in a tissue sample; (4) comparing the level of keratinocyte cells in step (1) to the level of keratinocyte cells in step (3), wherein a lack of increase or a decrease in keratinocyte cell level is indicative of suppressing or reducing proliferation or differentiation of keratinocyte cells.
- 28. A method of suppressing or reducing proliferation or differentiation of keratinocyte cells according to claim 27, wherein the antibody, antibody fragment or single chain antibody specifically binds to the IL-20RA subunit of the receptor of IL-20.
- 29. The method of claim 29, wherein the antibody, antibody fragment or single chain antibody is administered in combination with a lubricant, keratolytic, topical corticosteroid, topical vitamin D derivative, anthralin, systemic antimetabolite, methotrexate, psoralen-ultraviolet-light therapy (PUVA), etretinate, isotretinoin, cyclosporine, or calcipotriol.
REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a divisional application of U.S. application Ser. No. 09/746,359, filed Dec. 22, 2000, which claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application 60/171,969, filed Dec. 23, 1999 and U.S. Provisional Application No. 60/213,341 filed Jun. 22, 2000.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60171969 |
Dec 1999 |
US |
|
60213341 |
Jun 2000 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09746359 |
Dec 2000 |
US |
Child |
10424658 |
Apr 2003 |
US |